Guardant Health Q2 revenue $137.2M (+26% YoY); raises FY2023 revenue guidance to $545-550M

Guardant Health, Inc.

2023-Q2 EPS reported -$1.95 revenue$265,864,000

Revenue $137.2M (+26% YoY); clinical test volume 43,500 (+49%), biopharma tests 6,700 (+12%).
Net loss $72.8M vs $229.4M prior year (includes fair value changes); Non-GAAP net loss $88.7M.
Raised FY2023 revenue guidance to $545-550M (from $535-545M); expects operating expenses below 2022 levels.
Cash $1.2B; completed public offering raising $381M net; Guardant360 now covered by all major U.S. commercial insurers.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Guardant Health, Inc. reported the quarter ended June 30, 2023 results: revenue $137.2 million, net income $(0.67), EPS $(0.67). Guidance raised.

Period: the quarter ended June 30, 2023
Revenue: $137.2 million
Net income: $(0.67)
EPS: $(0.67)
Guidance: raised
Result: reported results

Exact text from the filing

Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance Q2 revenue increased 26% year over year driven by clinical volume growth of 49% Raises 2023 revenue guidance to $545 to $550 million PALO ALTO, Calif. August 3, 2023 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended June 30, 2023. Second Quarter 2023 Financial Highlights • Revenue of $137.2 million for the second quarter of 2023, an increase of 26% over the second quarter of 2022 • Reported 43,500 tests to clinical customers and 6,700 tests to biopharmaceutical customers in the second quarter of 2023, representing increases of 49% and 12%, respectively, over the second quarter of 2022 Recent Operating Highlights • Received new commercial plan coverage from Anthem Blue Cross and Blue Shield, Aetna,

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Guardant Health, Inc. filing history →

Source: SEC EDGAR

accession 0001576280-23-000121

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.